144.95
Irhythm Technologies Inc stock is traded at $144.95, with a volume of 443.05K.
It is up +0.10% in the last 24 hours and up +2.80% over the past month.
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
See More
Previous Close:
$144.81
Open:
$143.52
24h Volume:
443.05K
Relative Volume:
0.94
Market Cap:
$4.74B
Revenue:
$560.03M
Net Income/Loss:
$-150.66M
P/E Ratio:
-29.83
EPS:
-4.86
Net Cash Flow:
$-87.43M
1W Performance:
-2.41%
1M Performance:
+2.80%
6M Performance:
+58.50%
1Y Performance:
+51.38%
Irhythm Technologies Inc Stock (IRTC) Company Profile
Name
Irhythm Technologies Inc
Sector
Industry
Phone
415-632-5700
Address
699 8TH STREET, San Francisco, CA
Compare IRTC with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
IRTC
Irhythm Technologies Inc
|
144.95 | 4.74B | 560.03M | -150.66M | -87.43M | -4.86 |
![]()
ABT
Abbott Laboratories
|
132.28 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
SYK
Stryker Corp
|
373.37 | 147.15B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
BSX
Boston Scientific Corp
|
101.73 | 146.97B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
MDT
Medtronic Plc
|
86.17 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
73.27 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Irhythm Technologies Inc Stock (IRTC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-02-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Dec-03-24 | Resumed | Wells Fargo | Equal Weight |
Oct-04-24 | Initiated | Goldman | Neutral |
Jun-20-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Dec-11-23 | Upgrade | Citigroup | Neutral → Buy |
Jul-19-23 | Initiated | Robert W. Baird | Outperform |
Feb-07-23 | Initiated | Wells Fargo | Overweight |
Nov-07-22 | Upgrade | Wolfe Research | Underperform → Peer Perform |
Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
Apr-06-22 | Initiated | Wolfe Research | Underperform |
Feb-24-22 | Upgrade | Needham | Hold → Buy |
Jan-18-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jan-12-22 | Upgrade | BTIG Research | Neutral → Buy |
Jan-11-22 | Upgrade | Oppenheimer | Perform → Outperform |
Dec-21-21 | Resumed | Canaccord Genuity | Buy |
Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
Jun-02-21 | Downgrade | Citigroup | Buy → Neutral |
Apr-13-21 | Downgrade | BTIG Research | Buy → Neutral |
Apr-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
Feb-26-21 | Downgrade | Colliers Securities | Buy → Neutral |
Jan-29-21 | Reiterated | Needham | Hold |
Nov-17-20 | Downgrade | Oppenheimer | Outperform → Perform |
Sep-11-20 | Initiated | Needham | Hold |
Sep-02-20 | Initiated | Robert W. Baird | Neutral |
Aug-07-20 | Upgrade | Colliers Securities | Neutral → Buy |
Aug-05-20 | Upgrade | Oppenheimer | Perform → Outperform |
Mar-05-20 | Initiated | Citigroup | Buy |
Feb-06-20 | Initiated | BTIG Research | Buy |
Jan-10-20 | Initiated | William Blair | Outperform |
Jan-08-20 | Initiated | SunTrust | Buy |
Oct-22-19 | Initiated | Oppenheimer | Perform |
Feb-20-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Sep-13-18 | Reiterated | Canaccord Genuity | Buy |
Sep-06-18 | Initiated | Chardan Capital Markets | Buy |
Aug-02-18 | Upgrade | Dougherty & Company | Sell → Neutral |
Jul-16-18 | Downgrade | Dougherty & Company | Neutral → Sell |
Dec-01-17 | Initiated | Dougherty & Company | Neutral |
View All
Irhythm Technologies Inc Stock (IRTC) Latest News
Robbins LLP Informs iRhythm Technologies, Inc. (IRTC) Investors That the Class Action Beat the - Bluefield Daily Telegraph
Robbins LLP Informs iRhythm Technologies, Inc. (IRTC) Investors That the Class Action Beat the Motion to Dismiss - GlobeNewswire
iRhythm at 2025 Truist Securities MedTech Conference: Strategic Growth Plans - Investing.com
Discretionary Denials in Action: iRhythm Technologies Inc. v. Welch Allyn Inc. | ProskauerThe Patent Playbook - JD Supra
File Early or Risk Denial: iRhythm IPR Institution Denial Underscores the Importance of Filing IPR Petitions Sooner Rather Than Later | Regulatory Roundup | Insights - Vinson & Elkins LLP
Cardiovascular Digital Solutions Market Generated - openPR.com
iRhythm Creates a New Basis for Discretionary Denial - IPWatchdog.com
(IRTC) Investment Report - news.stocktradersdaily.com
iRhythm Technologies (NASDAQ:IRTC) shareholders have earned a 57% return over the last year - Yahoo Finance
iRhythm: Promising OutlookSo Long As Past Mistakes Are Not Repeated (NASDAQ:IRTC) - Seeking Alpha
iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
iRhythm Technologies (NASDAQ:IRTC) Given New $160.00 Price Target at Morgan Stanley - Defense World
iRhythm Technologies (IRTC) Price Target Raised by Morgan Stanle - GuruFocus
Insider Sell: Chad Patterson Sells Shares of iRhythm Technologies Inc - GuruFocus
IRTC to be Featured in Upcoming BTIG Event in New York | IRTC St - GuruFocus
iRhythm Technologies (IRTC) Price Target Raised by Morgan Stanley | IRTC Stock News - GuruFocus
iRhythm at Goldman Sachs Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Stewart's Newest Discretionary Denial Has Attys On Edge - Law360
iRhythm at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com
iRhythm (IRTC) Gains Momentum as Morgan Stanley Raises Price Tar - GuruFocus
iRhythm (IRTC) Gains Momentum as Morgan Stanley Raises Price Target | IRTC Stock News - GuruFocus
Morgan Stanley Raises iRhythm Technologies Price Target to $160 From $130, Maintains Overweight Rating - marketscreener.com
Cardiac Patch Monitor Market Outlook, Developments, and Strategic Insights by 2031 - openPR.com
Patent Chief Nixes iRhythm Challenges Citing Decade-Old Tech (1) - Bloomberg Law News
Stewart Grants Request to Deny IPR Institution Due to Patent Owner’s ‘Settled Expectations’ - IPWatchdog.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Stockholders to Connect - ACCESS Newswire
iRhythm Technologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Patent Office Leader Rejects IPRs Based On 12-Year Wait - Law360
iRhythm Technologies stock hits 52-week high at $147 By Investing.com - Investing.com South Africa
iRhythm Technologies stock hits 52-week high at $147 - Investing.com
Should You Hold iRhythm Technologies (IRTC)? - Insider Monkey
iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
U.S. Smart Wearable ECG Monitors Market Size Report 2030 - Grand View Research
Q1 Patient Monitoring Earnings: Insulet (NASDAQ:PODD) Earns Top Marks - Yahoo Finance
iRhythm at 45th Annual William Blair Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Heart Device Maker iRhythm Gets Investor Claims Trimmed - Law360
Global AI in Remote Patient Monitoring Market to Cross USD 13 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
iRhythm Fails to Snuff Investor Suit Over Heart Monitor Flaws - Bloomberg Law News
Healthcare Tech And Innovation: Heart Monitors Improving - Seeking Alpha
iRhythm Technologies Inc (IRTC) Stock Price Up 3.75% on Jun 3 - GuruFocus
Shareholders that lost money on iRhythm Technologies, Inc.(IRTC) should contact Levi & Korsinsky about pending Class ActionIRTC - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Smart Wearable ECG Monitors Market Size Report, 2030 - Grand View Research
INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of iRhythm Technologies, Inc. (IRTC) - ACCESS Newswire
(IRTC) Trading Signals - news.stocktradersdaily.com
Bronstein, Gewirtz & Grossman, LLC Encourages iRhythm Technologies, Inc. (IRTC) Investors to Inquire about Securities Investigation - ACCESS Newswire
iRhythm Technologies Holds 2025 Annual Stockholders Meeting - TipRanks
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against iRhythm Technologies, Inc. (IRTC) And Encourages Investors to Reach Out - ACCESS Newswire
iRhythm Technologies, Inc. (NASDAQ:IRTC) Shares Sold by Nuveen Asset Management LLC - Defense World
Millennium Management LLC Reduces Stake in iRhythm Technologies, Inc. (NASDAQ:IRTC) - Defense World
BNP Paribas Financial Markets Sells 7,391 Shares of iRhythm Technologies, Inc. (NASDAQ:IRTC) - Defense World
Irhythm Technologies Inc Stock (IRTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):